Compare GENNEX LABORATORIES with ALEMBIC PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GENNEX LAB. vs ALEMBIC PHARMA - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GENNEX LAB. ALEMBIC PHARMA GENNEX LAB./
ALEMBIC PHARMA
 
P/E (TTM) x 24.5 18.5 132.7% View Chart
P/BV x 3.2 2.9 111.3% View Chart
Dividend Yield % 0.0 1.9 -  

Financials

 GENNEX LAB.   ALEMBIC PHARMA
EQUITY SHARE DATA
    GENNEX LAB.
Mar-21
ALEMBIC PHARMA
Mar-21
GENNEX LAB./
ALEMBIC PHARMA
5-Yr Chart
Click to enlarge
High Rs61,150 0.5%   
Low Rs2527 0.3%   
Sales per share (Unadj.) Rs4.4274.4 1.6%  
Earnings per share (Unadj.) Rs0.356.7 0.6%  
Cash flow per share (Unadj.) Rs0.466.0 0.6%  
Dividends per share (Unadj.) Rs014.00 0.0%  
Avg Dividend yield %01.7 0.0%  
Book value per share (Unadj.) Rs3.1260.9 1.2%  
Shares outstanding (eoy) m126.50196.56 64.4%   
Bonus / Rights / Conversions ---  
Price / Sales ratio x0.93.1 29.3%   
Avg P/E ratio x12.314.8 83.5%  
P/CF ratio (eoy) x10.112.7 79.8%  
Price / Book Value ratio x1.33.2 39.0%  
Dividend payout %024.7 0.0%   
Avg Mkt Cap Rs m498164,818 0.3%   
No. of employees `000NANA-   
Total wages/salary Rs m7210,512 0.7%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m55653,931 1.0%  
Other income Rs m5875 0.6%   
Total revenues Rs m56254,806 1.0%   
Gross profit Rs m6214,801 0.4%  
Depreciation Rs m91,835 0.5%   
Interest Rs m7160 4.6%   
Profit before tax Rs m5113,681 0.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m102,533 0.4%   
Profit after tax Rs m4011,148 0.4%  
Gross profit margin %11.127.4 40.3%  
Effective tax rate %20.218.5 109.3%   
Net profit margin %7.320.7 35.1%  
BALANCE SHEET DATA
Current assets Rs m37725,779 1.5%   
Current liabilities Rs m19012,808 1.5%   
Net working cap to sales %33.524.1 139.2%  
Current ratio x2.02.0 98.3%  
Inventory Days Days4723 198.5%  
Debtors Days Days58,680,59624 248,737,279.2%  
Net fixed assets Rs m21241,311 0.5%   
Share capital Rs m127393 32.2%   
"Free" reserves Rs m27150,883 0.5%   
Net worth Rs m39751,276 0.8%   
Long term debt Rs m01,999 0.0%   
Total assets Rs m58967,090 0.9%  
Interest coverage x7.886.4 9.0%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.90.8 117.5%   
Return on assets %8.116.9 48.2%  
Return on equity %10.221.7 46.8%  
Return on capital %14.626.0 56.3%  
Exports to sales %41.266.8 61.7%   
Imports to sales %4.412.7 34.3%   
Exports (fob) Rs m22936,020 0.6%   
Imports (cif) Rs m246,845 0.4%   
Fx inflow Rs m22936,020 0.6%   
Fx outflow Rs m296,845 0.4%   
Net fx Rs m20129,175 0.7%   
CASH FLOW
From Operations Rs m-1414,634 -0.1%  
From Investments Rs mNA-8,388 0.0%  
From Financial Activity Rs m16-5,974 -0.3%  
Net Cashflow Rs m2262 0.6%  

Share Holding

Indian Promoters % 22.1 69.0 32.0%  
Foreign collaborators % 0.0 0.5 -  
Indian inst/Mut Fund % 0.0 17.5 -  
FIIs % 0.0 5.9 -  
ADR/GDR % 0.0 0.0 -  
Free float % 78.0 30.5 255.4%  
Shareholders   50,052 110,038 45.5%  
Pledged promoter(s) holding % 8.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GENNEX LAB. With:   SUN PHARMA    LUPIN    CIPLA    AUROBINDO PHARMA    DR. REDDYS LAB    



Today's Market

Sensex, Nifty Recover from Day's Low to End Higher; Maruti Suzuki Hits New High Post Q3 Results(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended higher.

Related Views on News

ALEMBIC PHARMA 2020-21 Annual Report Analysis (Annual Result Update)

Jul 8, 2021 | Updated on Jul 8, 2021

Here's an analysis of the annual report of ALEMBIC PHARMA for 2020-21. It includes a full income statement, balance sheet and cash flow analysis of ALEMBIC PHARMA. Also includes updates on the valuation of ALEMBIC PHARMA.

Why Did Alembic Pharma Shares Fall Today? (Views On News)

May 5, 2021

Covid-led supply disruptions of API fuel Alembic Pharma's global prospects.

3 Indian Pharma Companies that are Investing Big Time for the Future (Views On News)

Nov 9, 2021

In 2021, R&D of pharma companies roared to life in a never-before-seen way.

Sun Pharma vs Dr Reddy's: Which is Better? (Views On News)

Dec 16, 2021

In an extremely competitive market, two pharma companies are competing against each other to grab the top spot.

5 Stocks to Watch Out for Amid the Omicron Outbreak (Views On News)

Dec 3, 2021

As the new variant of Covid-19 emerges, keep an eye on these stocks.

More Views on News

Most Popular

Tata Steel vs SAIL: Which Stock is Better?(Views On News)

Jan 13, 2022

With government initiatives set to boost the steel sector, find out who has a better chance of coming out on top.

These 5 Penny Stocks are Held by Rakesh Jhunjhunwala. Worth a Look?(Views On News)

Jan 18, 2022

Rakesh Jhunjhunwala is holding these penny stocks in his portfolio for several years now.

Tech Mahindra's CTC Acquisition: Too Expensive?(Views On News)

Jan 18, 2022

Tech Mahindra's acquisition of European IT-company fails to excite investors.

Time to Buy Energy Stocks(Fast Profits Daily)

Jan 14, 2022

Energy is a sector that looks set to take off. It's time to get in.

5 Hidden Tata Group Companies to Add to Your Watchlist(Views On News)

Jan 18, 2022

Here's all you need to know about these five Tata group stocks that aren't as popular as the others.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GENNEX LAB. SHARE PRICE


Jan 25, 2022 (Close)

TRACK GENNEX LAB.

  • Track your investment in GENNEX LAB. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

GENNEX LAB. 5-YR ANALYSIS

COMPARE GENNEX LAB. WITH

MARKET STATS